Myozyme Temporary Access Program
ID Number 08-0453Principal Investigator(s)
Mark A. Sivak
Department(s) or Division(s)
The purpose of this study is to provide adult patients with Pompe disease in the United States (US) access to investigational Aglucosidase Alfa for a limited time until it is approved for commercial use by the Food and Drug Administration (FDA) and sufficient supply is available.
Recruiting Patients: Yes